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The Clinical Problem 
In a recently published case report, titled ‘The Tyranny of Guidelines,’ Sarosi 
recounts the story of an 86-year-old man living on his farm in Wisconsin and 
caring for his 92-year-old brother with early dementia (1). Six years earlier he 
had been started on an ACE inhibitor and metformin following a health check 
when he received his Medicaid card, with other oral agents subsequently 
added. But when his family practice was taken over by a large organisation, 
he was given a copy of the American Diabetes Association (ADA) guidelines, 
started on insulin in response to his HbA1c of 8.5%, and had his 
antihypertensive dose doubled because his blood pressure was 154/92. 
Three weeks later, he was admitted to hospital hypotensive and 
hypoglycaemic, with a hip fracture and a stroke. Both he and his brother 
subsequently needed residential care. The author pointed out the statement in 
the guidelines that ‘Older adults who are functional and cognitively intact and 
have significant life expectancy should receive diabetes care with goals 
similar to those developed for younger adults’ (2) – an HbA1c of 7% and a 
blood pressure of <140/90.  
Are Guidelines Over-Prescriptive or do they Provide the Tools Needed 
for Patient-Centred Care? 
The clinicians might claim they were only following guidelines. But when 
linked to quality measures and reimbursement, as happens for example in the 
US (3), and with the Quality and Outcomes Framework in the UK (4), 
guidelines can morph into orders. These guidelines suggest a target HbA1c 
below 8% and blood pressure of <140/90 in elderly patients unless their 
health status is ‘very complex/poor … (long-term care … end-stage chronic 
illnesses or moderate- to-severe cognitive impairment)’ with limited remaining 
life expectancy (2).  And while the ADA and the European Association for the 
Study of Diabetes, recommend that ‘where possible, such decisions should be 
made with the patient, reflecting his or her preferences, needs and values’ (5), 
they provide no tools for quantifying the harm associated with a particular risk 
factor nor information comparing likely benefits and harms of treatments (6). 
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We argue that such tools, based on patient-relevant outcomes including gains 
in healthy life expectancy, are vitally needed – not just for shared decision-
making, but also better to inform clinicians, guideline committees and 
comparative effectiveness agencies. In this man’s case, an outcome model 
would have estimated that his treatment changes would have extended 
healthy life expectancy by no more than 5 weeks (7,8). 
 
The National Institute for Health and Care Excellence (NICE) updated its 
guidelines for management of adults with type 2 diabetes in December 2015 
(9). The targets for NICE are similar to, but in some cases even more 
aggressive than, the above mentioned guidelines. They recommend an 
HbA1c of 7% (or 6.5% if it can be achieved by a single drug which does not 
cause hypoglycaemia) and a blood pressure <140/80, although these targets 
might be relaxed in ‘people who are older or frail … (  or) with a reduced life 
expectancy.’ NICE also states ‘patients should have the opportunity to make 
informed decisions about their care and treatment, in partnership with their 
healthcare professionals.’ But although the guidelines provide a useful 
decision aid for treatment risks by giving rates of adverse effects including 
hypoglycaemia, and examples of such frequencies as pictograms (eg 1 in 
1000) (10), the only information on possible benefits is provided separately in 
the ‘decision aid user guide for healthcare professionals,’ and in the form of 
relative risk reductions (11). No information is provided to allow clinicians to 
quantify the risks associated with different levels of risk factors or their  
change, surely something which NICE or the ADA could have included, or 
commissioned, had it been considered important. 
What Might The Patient Have Asked, and Been Told? 
In the context of a patient resembling the one we have presented, let us 
speculate how such a conversation about his glycaemic control might go 
using the information in the NICE guideline (Table). With the information in the 
user guide, he would be told that getting his HbA1c down by 1% might reduce 
his risk of a non-fatal myocardial infarction by 13% (a relative benefit), but the 
healthcare professional could not have given any indication of the baseline 
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risk in the first place nor the possible gains in healthy life expectancy. He 
might be told, based on the guidelines, that it was important to improve his 
glucose control to prevent blindness or renal failure. However he would not 
have been told the evidence for this benefit is extrapolated from a 20%-25% 
reduction in surrogate endpoints (retinal photocoagulation and proteinuria 
changes) rather than there being virtually no evidence for glucose control 
actually reducing risks of blindness and ESRD (12). He would also not have 
been told his lifetime risks of these events are at most 1-2% (13). Fully 
informed decision-making needs fully informed clinicians as well as patients.  
Table  
Likely benefits from starting insulin in the patient described* 
Glycated haemoglobin – reduction of 1% 
Cardiovascular disease  
 Fatal – no impact 
 Non-fatal – RRR 13% 
ARR 3.7% at 10 years   
Blindness – RRR 25% (extracted from surrogate endpoints) 
ARR 2.3% at 10 years 
End Stage Renal Failure – RRR 25% (extracted from surrogate 
endpoints) 
- ARR 0.03% at 10 years 
Life expectancy gain – approximately 5 weeks 
*The estimates are derived from the UKPDS-Outcomes Model 2 (ref 8) 
 
Treating Risk Factors – For Individual or For Population Benefit? 
Absolute risk reductions and numbers needed to treat are now more widely 
disseminated, but the fact is that when translated into gains in healthy life 
expectancy these are, at best, moderate (14). Moreover, in a person with a 10 
 5 
year cardiovascular risk of 40%, 9 out of 10 people started on a statin (relative 
risk reduction ~25%, but, in this patient, absolute risk reduction of 10%) will 
not derive a clinical benefit over that timespan. In people at much lower risk, 
or in those treated with less effective strategies (like glucose lowering) (15), 
the interventions might be considered more for the benefit of public health – 
reducing population disease incidence -  rather than anything an individual 
might deem as worthwhile. This is something of which many clinicians are 
unaware when they write prescriptions (14,16,17). In one study, physicians 
presented with 3 ‘grey cases’ grossly overestimated the probable benefits of 
intensifying glucose control (median around 7 years versus around 5 weeks 
from an outcomes model) and blood pressure lowering (~7 years versus ~10 
weeks) (14). This over-optimism underlies the need for better tools to estimate 
likely harms, benefits and risks. Such tools might also inform the NICE 
guideline development group as to what are the likely additional benefits from 
reducing target HbA1c to 6.5% (8,18). 
Shared Decision-Making Needs Time, Plus Tools, to Allow 
Patients to Make Informed choices 
 In its professional guidance, the UK’s General Medical Council (GMC) 
advises doctors that their role is to outline the benefits, risks and 
burdens of a treatment or procedure in clear and understandable 
fashion, but it is the patient who weighs up the information, together 
with other relevant issues, and makes the decision (19). A recent UK 
Supreme Court judgment concerning the information provided to a 
woman with diabetes about the benefits and risks of a caesarean 
section for her and her fetus, has now configured legal obligations with 
ethical guidance (20). The Montgomery judgment highlighted the 
importance of shared decision-making that is properly informed; this 
may be interpreted as establishing a new legal requirement that 
information about the potential harms and benefits of a proposed 
course of action should be communicated accurately (21).   
In the context of treating risk factors, two other considerations often 
apply – the patient is typically asymptomatic, and the treatment has 
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the potential of being life-long. Individuals respond very differently in 
their aversion to taking regular medication (22, 23) so guidelines need 
to facilitate choices that are consistent with that person’s priorities 
(24). While many patients will still demur to their clinician in decisions 
about such treatment, it is surely incumbent upon guideline developers 
to include, or at least provide some directions to, appropriately 
developed and properly tested (24) shared decision-making tools that 
could be used (Box). If guideline writers decide that existing tools need 
further work, we suggest it is incumbent upon them at least to provide 
some ballpark figures that clinicians can use. Moreover, because 
people respond in a variety of ways to different formats for explaining 
benefits (25), such tools and figures need similarly to show estimates 
of benefit in a variety of formats -absolute risk reductions (ARR), 
numbers needed to treat (NNT), and gains in healthy life expectancy 
(8,14,25,26). Furthermore, the multiplicity of complications of diabetes, 
which benefit to different degrees from improved glycaemic control, 
makes for problems in expressing benefit as ARR or NNT (15). 
Because of this, a model-derived summary measure, such as gains in 
healthy life years, may be more relevant when it comes to intensive 
glucose lowering (8).  
The impact of glucose lowering in people with type 2 diabetes on such 
summary measures is likely quantified in weeks or months (8,14), 
rather than years. This should also influence the agenda of cost-
effectiveness agencies, which explicitly accept this concept in cancer 
treatments but perhaps not for diabetes. Such summary measures 
might permit a more patient specific assessment of the value of 
glucose lowering medication. Token statements such as ‘patients 
should have the opportunity to make informed decisions about their 
care and treatment, in partnership with their healthcare professionals’ 
do not make for patient-centered guidelines. If guideline writers with all 
their expertise and resources can’t come up with specific tools or 
approaches, it is improbable that individual users will be able to fill in 
the knowledge translation blanks left by these guidelines. 
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BOX  
Estimating benefits of interventions for cardiovascular risk factor 
lowering  
 
A variety of tools have been developed to inform the shared decision-
making process, using a variety of prediction models and interfaces, 
and ranking different treatments or estimating their benefits with 
different measures. Their use is summarised in ref 27.  
 
 The Absolute CVD Risk/Benefit Calculator 
(http://chd.bestsciencemedicine.com/calc2.html). 
 Mayo Clinic Heart Disease Risk Calculator 
(http://www.mayoclinic.org/diseases-conditions/heart-disease/in-
depth/heart-disease-risk/itt-20084942) 
 Mayo Clinic Diabetes Decision Aid 
(https://diabetesdecisionaid.mayoclinic.org/index.php/site/compa
re?PHPSESSID=k3sgf2rju1t2bpo8738bf95354 and ref 27). 
 Healthy Living for People with Diabetes web-based self-
management programme (ref 25). 
 United Kingdom Prospective Diabetes Study – Outcomes Model 
1 and 2 (refs 7,26). 
 London School of Economics Statin Ranking Tool* 
(http://www.lse.ac.uk/IPA/ResearchAndEngagement/ProjectArchi
ve/VisualisingData/StatinRankingTool.aspx). 
 
* While this is not a diabetes decision aid, it shows how it is possible to 
integrate comparative treatment rankings from network meta-analysis 
with patient preferences in decision-making. 
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